Shuttle Pharmaceuticals to present Phase 2 trial updates and diagnostic advancements at Planet MicroCap Showcase in Las Vegas.
Quiver AI Summary
Shuttle Pharmaceuticals Holdings, Inc. has announced its participation in the Planet MicroCap Showcase: VEGAS 2025, where Dr. Anatoly Dritschilo, the company's Chairman and Chief Scientific Officer, will present on April 23, 2025. The presentation will provide insights into the ongoing Phase 2 trial of Ropidoxuridine for glioblastoma treatment and updates from the Company’s Shuttle Diagnostics subsidiary, which is developing diagnostic tests for prostate cancer. Attendees can access the presentation live at the Paris Hotel & Casino in Las Vegas at 2:30 p.m. Pacific Time, with opportunities for one-on-one meetings with management available for interested parties. Shuttle Pharma focuses on enhancing cancer treatment outcomes through the development of therapies that improve the efficacy of radiation therapy while minimizing side effects.
Potential Positives
- Shuttle Pharmaceuticals will present at the Planet MicroCap Showcase: VEGAS 2025, which provides an opportunity to increase visibility and attract interest from potential investors.
- Dr. Anatoly Dritschilo will provide an update on the ongoing Phase 2 trial of Ropidoxuridine and radiation therapy for glioblastoma, highlighting the company's commitment to innovative cancer treatment.
- The presentation will also include advancements from Shuttle Diagnostics in developing diagnostic tools for prostate cancer, showcasing the company's diversified approach in cancer treatment and diagnostics.
Potential Negatives
- The press release emphasizes ongoing developments in clinical trials, which may signal that the company has not yet achieved significant milestones or product approvals, indicating potential risks in its current stage of development.
- The inclusion of a detailed "Safe Harbor Statement" suggests that the company may be anticipating uncertainties or challenges in achieving its future goals, which could raise red flags for investors.
- The mention of risk factors and the reliance on forward-looking statements may reflect instability or concerns about the company's future performance and financial health, potentially leading to investor apprehension.
FAQ
What is the upcoming event for Shuttle Pharmaceuticals?
Shuttle Pharmaceuticals will present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025.
Who will be leading the Shuttle Pharmaceuticals presentation?
Anatoly Dritschilo, M.D., Chairman and Chief Scientific Officer, will host the presentation.
What will be discussed during the presentation?
The presentation will cover the Phase 2 trial of Ropidoxuridine and advancements in Shuttle Diagnostics.
How can I access the live presentation?
You can access the live presentation via this link: https://event.summitcast.com/view/YNz6mnmEsXyrdRxb78w2nX/Js2DcQMoTdPkzijmn5bhuj.
How can investors schedule a meeting with Shuttle Pharmaceuticals management?
Investors can schedule a 1x1 meeting through their Planet MicroCap representative or by contacting the investor relations team.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
GAITHERSBURG, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). Anatoly Dritschilo, M.D., Chairman of the Board of Directors and Chief Scientific Officer of Shuttle Pharma, will be hosting the presentation and answering questions at the conclusion.
Dr. Dritschilo’s presentation will focus on providing an overview and update on the Company’s ongoing Phase 2 trial of Ropidoxuridine and RT for treatment of patients with glioblastoma as well as advancements being made in the Company’s Shuttle Diagnostics subsidiary which aims to develop pretreatment diagnostic blood tests and imaging agents for prostate cancer patients.
To access the live presentation, please use the following information:
Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub
Date: Wednesday, April 23, 2025
Time: 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time)
Location: Track 3 – Chablis at the Paris Hotel & Casino in Las Vegas, NV
Webcast:
https://event.summitcast.com/view/YNz6mnmEsXyrdRxb78w2nX/Js2DcQMoTdPkzijmn5bhuj
If you would like to schedule a 1x1 meeting with management, please contact your Planet MicroCap representative or the Company’s investor relations team at
1x1@lythampartners.com
. 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at
www.shuttlepharma.com
.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D.
Chairman and Chief Scientific Officer
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
